Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17(8):487–500.

CAS  PubMed  Article  Google Scholar 

Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, Han J, Wei X. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4(1):1–39.

Article  Google Scholar 

Morera L, Lübbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenet. 2016;8(1):1–6.

Article  CAS  Google Scholar 

Hyun K, Jeon J, Park K, Kim J. Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017;49(4):e324.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol. 2005;19(3):563–73.

CAS  PubMed  Article  Google Scholar 

Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(3):245–54.

CAS  PubMed  Article  Google Scholar 

Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13(5):343–57.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Jambhekar A, Dhall A, Shi Y. Roles and regulation of histone methylation in animal development. Nat Rev Mol Cell Biol. 2019;20(10):625–41.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Fallah MS, Szarics D, Robson CM, Eubanks JH. Impaired regulation of histone methylation and acetylation underlies specific neurodevelopmental disorders. Front Genet. 2021;11:1734.

Article  CAS  Google Scholar 

Burg JM, Link JE, Morgan BS, Heller FJ, Hargrove AE, McCafferty DG. KDM1 class flavin-dependent protein lysine demethylases. Pept Sci. 2015;104(4):213–46.

CAS  Article  Google Scholar 

D’Oto A, Tian QW, Davidoff AM, Yang J. Histone demethylases and their roles in cancer epigenetics. J Med Oncol Ther. 2016;1(2):34.

PubMed  PubMed Central  Google Scholar 

Swigut T, Wysocka J. H3K27 demethylases, at long last. Cell. 2007;131(1):29–32.

CAS  PubMed  Article  Google Scholar 

Eskeland R, Leeb M, Grimes GR, Kress C, Boyle S, Sproul D, Gilbert N, Fan Y, Skoultchi AI, Wutz A, Bickmore WA. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol Cell. 2010;38(3):452–64.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, Zhang Y. Role of histone H2A ubiquitination in polycomb silencing. Nature. 2004;431(7010):873–8.

CAS  PubMed  Article  Google Scholar 

Hansen KH, Bracken AP, Pasini D, Dietrich N, Gehani SS, Monrad A, Rappsilber J, Lerdrup M, Helin K. A model for transmission of the H3K27me3 epigenetic mark. Nat Cell Biol. 2008;10(11):1291–300.

CAS  PubMed  Article  Google Scholar 

Hugues A, Jacobs CS, Roudier F. Mitotic inheritance of PRC2-mediated silencing: mechanistic insights and developmental perspectives. Front Plant Sci. 2020;9(11):262.

Article  Google Scholar 

Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, Eberhard D. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012;488(7411):404–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Heinemann B, Nielsen JM, Hudlebusch HR, Lees MJ, Larsen DV, Boesen T, Labelle M, Gerlach LO, Birk P, Helin K. Inhibition of demethylases by GSK-J1/J4. Nature. 2014;514(7520):E1-2.

CAS  PubMed  Article  Google Scholar 

Enane FO, Saunthararajah Y, Korc M. Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death Dis. 2018;9(9):1–5.

CAS  Article  Google Scholar 

Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016;8(9): a019505.

PubMed  PubMed Central  Article  CAS  Google Scholar 

De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.

PubMed  PubMed Central  Article  Google Scholar 

Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F. Acute myeloid leukemia: Current progress and future directions. Blood Cancer J. 2021;11(2):1–25.

Article  Google Scholar 

Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21(8):1–1.

Article  Google Scholar 

Li Y, Zhang M, Sheng M, Zhang P, Chen Z, Xing W, Bai J, Cheng T, Yang FC, Zhou Y. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia. J Cancer Res Clin Oncol. 2018;144(6):1065–77.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Stief SM, Hanneforth AL, Weser S, Mattes R, Carlet M, Liu WH, Bartoschek MD, Moreno HD, Oettle M, Kempf J, Vick B. Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia. 2020;34(1):50–62.

PubMed  Article  Google Scholar 

Fattizzo B, Rosa J, Giannotta JA, Baldini L, Fracchiolla NS. The physiopathology of T-cell acute lymphoblastic leukemia: focus on molecular aspects. Front Oncol. 2020;10:273.

PubMed  PubMed Central  Article  Google Scholar 

Raetz EA. Teachey DT 2016 T-cell acute lymphoblastic leukemia. Hematol 2014 Am Soc Hematol Educ Progr Book. 2016;1:580–8.

Google Scholar 

Ntziachristos P, Tsirigos A, Welstead GG, Trimarchi T, Bakogianni S, Xu L, Loizou E, Holmfeldt L, Strikoudis A, King B, Mullenders J. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature. 2014;514(7523):513–7.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F, Matthijssens F, Rondou P, Rosen M, Pieters T, Vandenberghe P, Delabesse E. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia Blood. J Am Soc Hematol. 2015;125(1):13–21.

Google Scholar 

Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DA, Kurupi RI, Calbert ML, Ghotra MS, Greninger P, Dozmorov M, Gowda M. Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. Sci Transl Med. 2018;10:441.

Article  CAS  Google Scholar 

Yang L, Zha Y, Ding J, Ye B, Liu M, Yan C, Dong Z, Cui H, Ding HF. Histone demethylase KDM6B has an anti-tumorigenic function in neuroblastoma by promoting differentiation. Oncogenesis. 2019;8(1):1–2.

Article  CAS  Google Scholar 

Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol. 2021;28:1–5.

Google Scholar 

Zhang J, Ying Y, Li M, Wang M, Huang X, Jia M, Zeng J, Ma C, Zhang Y, Li C, Wang X. Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer. Theranostics. 2020;10(22):10016.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wang Q, Chen X, Jiang Y, Liu S, Liu H, Sun X, Zhang H, Liu Z, Tao Y, Li C, Hu Y. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin. J Mol Cell Biol. 2020;12(2):125–37.

CAS  PubMed  Article  Google Scholar 

Rebello RJ, Christoph O, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Silke G, Bristow RG. Prostate cancer (Primer). Nat Rev Dis Primers. 2021. https://doi.org/10.1038/s41572-020-00243-0.

Article  PubMed  Google Scholar 

Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(s2):72–9.

Article  Google Scholar 

Morozov VM, Li Y, Clowers MM, Ishov AM. Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer. Oncotarget. 2017;8(37):62131.

PubMed  PubMed Central  Article  Google Scholar 

Harbeck M, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F. Breast cancer. Nat Rev Dis Primers. 2019. https://doi.org/10.1038/s41572-019-0111-2.

Article  PubMed  Google Scholar 

Yan N, Xu L, Wu X, Zhang L, Fei X, Cao Y, Zhang F. GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells. Exp Cell Res. 2017;359(2):405–14.

CAS  PubMed  Article  Google Scholar 

Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, Gianni L, Castiglione M, Gelber RD, Coates AS, Goldhirsch A. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34(9):927.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Wang W, Lim KG, Feng M, Bao Y, Lee PL, Cai Y, Chen Y, Zhang H, Marzese D, Hoon DS, Yu Q. KDM6B counteracts EZH2-mediated suppression of IGFBP5 to confer resistance to